Collegium Pharmaceutical (NASDAQ:COLL) Receives Neutral Rating from Piper Sandler

Piper Sandler reaffirmed their neutral rating on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a research report sent to investors on Friday morning, Benzinga reports. The brokerage currently has a $37.00 target price on the specialty pharmaceutical company’s stock.

Several other analysts also recently commented on COLL. Needham & Company LLC reissued a hold rating on shares of Collegium Pharmaceutical in a research report on Friday, August 9th. HC Wainwright increased their price target on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a buy rating in a report on Thursday, September 5th. StockNews.com lowered shares of Collegium Pharmaceutical from a strong-buy rating to a buy rating in a report on Saturday, August 31st. Finally, Truist Financial increased their target price on Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a buy rating in a research note on Friday, August 9th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of Moderate Buy and an average price target of $42.60.

Collegium Pharmaceutical Trading Up 0.7 %

Shares of NASDAQ COLL opened at $38.00 on Friday. The stock has a market cap of $1.24 billion, a P/E ratio of 15.83 and a beta of 0.94. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.11 and a quick ratio of 1.04. Collegium Pharmaceutical has a 1 year low of $20.95 and a 1 year high of $42.29. The firm has a 50-day moving average of $37.27 and a 200 day moving average of $35.44.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.22. The company had revenue of $145.28 million for the quarter, compared to the consensus estimate of $143.94 million. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The firm’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.13 EPS. As a group, sell-side analysts expect that Collegium Pharmaceutical will post 5.79 EPS for the current fiscal year.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, EVP Thomas B. Smith sold 9,593 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $36.62, for a total value of $351,295.66. Following the completion of the sale, the executive vice president now owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $38.30, for a total value of $737,198.40. Following the transaction, the executive vice president now owns 120,161 shares of the company’s stock, valued at approximately $4,602,166.30. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Thomas B. Smith sold 9,593 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The shares were sold at an average price of $36.62, for a total transaction of $351,295.66. Following the sale, the executive vice president now directly owns 53,816 shares of the company’s stock, valued at approximately $1,970,741.92. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.98% of the stock is owned by insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of hedge funds have recently modified their holdings of the business. Gladius Capital Management LP purchased a new position in Collegium Pharmaceutical during the second quarter valued at $32,000. nVerses Capital LLC raised its stake in shares of Collegium Pharmaceutical by 1,600.0% in the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 1,600 shares during the period. GAMMA Investing LLC raised its stake in shares of Collegium Pharmaceutical by 124.5% in the third quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 792 shares during the period. CWM LLC lifted its position in shares of Collegium Pharmaceutical by 97.5% during the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after buying an additional 736 shares in the last quarter. Finally, Sheaff Brock Investment Advisors LLC bought a new position in shares of Collegium Pharmaceutical during the 1st quarter valued at approximately $204,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.